Dual effect of pre-ischemic administration of TNF-alpha on myocardial infarct size


Tumour necrosis factor-α is a cytokine released during myocardial infarction. According to the literature, the effect of TNFα on myocardial infarction is controversial, especially when administered before the ischemic period. The deleterious effects of TNFα seem to be related to the triggering of apoptosis. This study has been designed to determine if different doses of TNFα, administered before the ischemic period, have the same effect on infarct size and on activation of caspase-3 and-8, two enzymes involved in apoptosis. Four groups, using a porcine model of myocardial infarction, have been used: placebo and TNFα (0.1 μg/kg; 1 μg/kg and 3 μg/kg). All administered 15 minutes before a 50 minutes occlusion of the left anterior descending artery. Myocardial infarct size has been determined at 3 hours of reperfusion. In a subgroup of animals, reperfusion period has been limited to 15 min to determine the activity of caspase-3 and-8 by spectrofluorometry. Results indicated that infarct size is significantly smaller in groups 0.1 μg/kg and 1 μg/ kg as compared to the placebo group. In contrast, the 3 μg/kg group presented an infarct size similar to the placebo group. Activity of caspase-3 and-8 is reduced in the ischemic region in groups 0.1 and 1 μg/ kg as compared to the placebo group whereas activity in the 3 μg/kg group was similar to the placebo. The results obtained indicated that a low dose of TNFα administered before the ischemic period reduces infarct size, whereas the cardioprotection is lost with the high dose.

Share and Cite:

Quang, T. , Hatem, R. , Rousseau, G. , Gosselin, A. , Schampaert, E. and Charron, T. (2013) Dual effect of pre-ischemic administration of TNF-alpha on myocardial infarct size. World Journal of Cardiovascular Diseases, 3, 21-25. doi: 10.4236/wjcd.2013.35A004.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kleinbongard, P., Schulz, R. and Heusch, G. (2011) TNF-alpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Failure Reviews, 16, 46-69.
[2] Levine, B., et al. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 323, 236-241. doi:10.1056/NEJM199007263230405
[3] Przyklenk, K., et al. (1993) Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation, 87, 893-899. doi:10.1161/01.CIR.87.3.893
[4] Mann, D.L. (2002) Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988-998. doi:10.1161/01.RES.0000043825.01705.1B
[5] Sack, M.N. and Yellon, D.M. (2003) Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: A proposed direct myocardial cell survival effect independent of metabolic modulation. Journal of the American College of Cardiology, 41, 1404-1407. doi:10.1016/S0735-1097(03)00164-5
[6] Deuchar, G.A., Opie, L.H. and Lecour, S. (2007) TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. Life Science, 80, 1686-1691. doi:10.1016/j.lfs.2007.01.040
[7] Lecour, S., Rochette, L. and Opie, L. (2005) Free radicals trigger TNF alpha-induced cardioprotection. Cardiovascular Research, 65, 239-243. doi:10.1016/j.cardiores.2004.10.003
[8] Kaloustian, S., et al. (2009) Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis, 14, 1308-1316. doi:10.1007/s10495-009-0395-x
[9] Maekawa, N., et al. (2002) Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. Journal of the American College of Cardiology, 39, 1229-1235. doi:10.1016/S0735-1097(02)01738-2
[10] Bradley, J.R. (2008) TNF-mediated inflammatory disease. Journal of Pathology, 214, 149-160. doi:10.1002/path.2287
[11] Boucher, M., et al. (2002) Alterations of beta-adrenoceptor responsiveness in postischemic myocardium after 72 h of reperfusion. European Journal of Pharmacology, 495, 185-191. doi:10.1016/j.ejphar.2004.05.040
[12] Wann, B.P., et al. (2006) Apoptosis detected in the amygdala following myocardial infarction in the rat. Biological Psychiatry, 59, 430-433. doi:10.1016/j.biopsych.2005.07.018
[13] Boucher, M., et al. (2006) Reduction of apoptosis in the amygdala by an A2A adenosine receptor agonist following myocardial infarction. Apoptosis, 11, 1067-1074. doi:10.1007/s10495-006-6313-6
[14] Belosjorow, S., et al. (2003) TNF-a antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. American Journal of Physiology, 284, H927-H930.
[15] Gu, Q., et al. (2006) Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. Journal of Cardiovascular Pharmacology, 48, 320-328. doi:10.1097/01.fjc.0000250079.46526.38
[16] Sugano, M., et al. (2004) In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB Journal, 18, 911-913.
[17] Lecour, S., et al. (2002) Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. Journal of Molecular and Cellular Cardiology, 34, 509-518. doi:10.1006/jmcc.2002.1533
[18] Duran, W.N. (2008) The double-edge sword of TNF-alpha in ischemia-reperfusion injury. American Journal of Physiology—Heart and Circulatory Physiology, 295, H2221-H2222. doi:10.1152/ajpheart.01050.2008
[19] Reil, J.C., et al. (2007) Insights from knock-out models concerning postischemic release of TNFalpha from isolated mouse hearts. Journal of Molecular and Cellular Cardiology, 42, 133-141. doi:10.1016/j.yjmcc.2006.09.020
[20] McVey, M., Perrone, M.H. and Clark, K.L. (1999) Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats? General Pharmacology, 32, 41-45. doi:10.1016/S0306-3623(98)00050-0
[21] Hausenloy, D.J., Tsang, A. and Yellon, D.M. (2005) The reperfusion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends in Cardiovascular Medicine, 15, 69-75. doi:10.1016/j.tcm.2005.03.001
[22] Lecour, S. (2009) Multiple protective pathways against reperfusion injury: A SAFE path without Aktion? Journal of Molecular and Cellular Cardiology, 46, 607-609. doi:10.1016/j.yjmcc.2009.01.003
[23] Boucher, M., et al. (2004) Post-ischemic cardioprotection by A2A adenosine receptors: Dependent of phosphatidylinositol 3-kinase pathway. Journal of Cardiovascular Pharmacology, 43, 416-422. doi:10.1097/00005344-200403000-00013

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.